Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. (RMD) filed a Form 4 reporting a routine insider transaction by director Harjit Gill. On 11/11/2025, 38.209 shares of ResMed common stock were disposed of under transaction code F at a $250.1 price to cover taxes upon vesting of previously granted RSUs. Following this withholding event, Gill beneficially owns 9,867 shares, held directly. The filing notes the RSUs were originally granted on 11/20/2024. This reflects administrative tax withholding rather than an open‑market sale.
ResMed Inc. (RMD) director Mr. Farrell reported two recent stock transactions. On 11/11/2025, he disposed of 162.953 shares of ResMed common stock at $250.10 per share, sent back to the company to cover taxes on the vesting of restricted stock units granted on 11/20/2024. On 11/12/2025, he sold 2,000 shares of ResMed common stock at an average price of $252.05 per share in an open-market transaction. After these actions, he beneficially owns 66,110 shares directly. The sale on 11/12/2025 was made under a Rule 10b5-1 trading plan adopted on August 12, 2025.
ResMed Inc. (RMD) Chairman and CEO Michael Farrell, who is also a director, reported routine share dispositions related to tax withholding on restricted stock unit (RSU) vesting. On 11/11/2025, he disposed of 2,231.545, 3,459.325, and 2,205.697 shares of ResMed common stock back to the issuer at a price of $250.1 per share, each coded "F" to indicate they were withheld for taxes upon RSU vesting from grants dated 11/16/2022, 11/16/2023, and 11/16/2024. After these transactions, Farrell beneficially owned 459,969 ResMed shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
ResMed Inc. director Jan De Witte reported stock transactions in company shares. On 11/11/2025, he sold 487 shares of ResMed common stock at $250.25 per share under a pre-arranged Rule 10b5-1 trading plan adopted on Feb 03, 2025. On the same date, 76.449 shares were disposed of to the issuer to cover tax withholding tied to the vesting of previously granted restricted stock units from 11/20/2024. After these transactions, he directly owned 5,242 shares of ResMed common stock.
ResMed Inc. (RMD) reported an insider transaction by Michael J. Rider, Global General Counsel, on 11/11/2025. The filing shows issuer share withholdings for taxes upon RSU vesting (transaction code F).
Withholdings were 135.075, 173.725, 715.489, and 500.735 shares of common stock at $250.1 per share, tied to RSU grants dated 11/18/2021, 11/16/2022, 11/16/2023, and 11/20/2024. After these transactions, Rider beneficially owned 9,841 shares directly. Holdings include 38.9396 shares acquired on 10/31/2025 through the ResMed Employee Stock Purchase Plan.
ResMed (RMD): Form 144 filed for a planned sale of up to 2,000 common shares. The notice lists an aggregate market value of $504,100, with sales expected on or about 11/12/2025 on the NYSE through Merrill Lynch (2049 Century Park East, Ste 1200, Los Angeles, CA 90067). This is a resale by a security holder under Rule 144; proceeds would go to the seller, not the company.
The filing shows the issuer had 44,448,959 shares outstanding. The shares to be sold were acquired on 09/01/2014 via a stock option for cash, in the amount of 2,000 shares, from Peter C Farrell.
ResMed (RMD) received a Form 144 notice for a proposed sale of 487 common shares, with an aggregate market value of $121,871.75. The approximate sale date is 11/11/2025 on the NYSE through Fidelity Brokerage Services.
The shares were acquired via restricted stock vesting on 11/11/2025 as compensation. Shares outstanding were 145,966,294 as of the filing; this is a baseline figure, not the amount being sold.
ResMed Inc. (RMD) reported insider activity by Chairman and CEO Michael J. Farrell. On 11/07/2025, he exercised stock options at $101.64 for 983 shares and 7,028 shares, and sold 8,011 shares at a weighted average price of $249.7532 (multiple trades between $248.13 and $251.46). The transactions were made pursuant to a Rule 10b5-1 plan adopted October 31, 2024.
Following these transactions, Farrell beneficially owned 467,866 shares directly and 2,090 shares indirectly via the Lisette and Michael Farrell Family Trust. Notes indicate options first became exercisable on 11/11/2019 and vest one-third per year, with expiration on 11/14/2025, and that holdings include 74.3412 shares purchased through the Employee Stock Purchase Plan on October 31, 2025.
ResMed (RMD) received a Form 144 notice for a proposed insider sale. The filing lists 8,011 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $2,000,773.19 and an approximate sale date of November 7, 2025.
The shares were acquired via an option originally granted on November 14, 2018, with acquisition and cash payment dated November 7, 2025. As context, the filing shows 145,966,294 shares outstanding. Recent activity disclosed in the notice includes three prior sales of 8,009 shares each on August 7, 2025, September 8, 2025, and October 7, 2025, with gross proceeds of $2,238,378.55, $2,227,590.42, and $2,265,332.03, respectively.
The notice indicates sales may occur using standard brokerage methods on a national exchange.
ResMed (RMD) reported a Form 4 for CFO Brett Sandercock. On 11/03/2025, he exercised 2,000 stock options at $101.64 (code M) and sold 3,000 shares at $247.54 (code S). Following these transactions, he directly beneficially owns 85,745 shares. The activity was conducted under a Rule 10b5-1 plan adopted on February 19, 2025. The exercised options were from a grant first exercisable on 11/11/2019 and vest 1/3 per year, expiring 11/14/2025.